Literature DB >> 20175882

German cancer statistics 2004.

Jörg Haberland1, Joachim Bertz, Ute Wolf, Thomas Ziese, Bärbel-Maria Kurth.   

Abstract

BACKGROUND: For years the Robert Koch Institute (RKI) has been annually pooling and reviewing the data from the German population-based cancer registries and evaluating them together with the cause-of-death statistics provided by the statistical offices. Traditionally, the RKI periodically estimates the number of new cancer cases in Germany on the basis of the available data from the regional cancer registries in which registration is complete; this figure, in turn, forms the basis for further important indicators.
METHODS: This article gives a brief overview of current indicators - such as incidence, prevalence, mortality, survival rates - on the most common types of cancer, as well as important ratios on the risks of developing and dying of cancer in Germany.
RESULTS: According to the latest estimate, there were a total of 436,500 new cancer cases in Germany in 2004. The most common cancer in men is prostate cancer with over 58,000 new cases per annum, followed by colorectal and lung cancer. In women, breast cancer remains the most common cancer with an estimated 57,000 new cases every year, also followed by colorectal cancer. These and further findings on selected cancer sites can be found in the current brochure on "Cancer in Germany", which is regularly published by the RKI together with the Association of Population-based Cancer Registries in Germany (GEKID). In addition, the RKI made cancer-prevalence estimates and calculated current morbidity and mortality risks at the federal level for the first time. According to these figures, the 5-year partial prevalence - i.e. the total number of cancer patients diagnosed over the past five years who are currently still living - exceeds 600,000 in men; the figure is about the same among women. Here, too, the most common cancers are prostate cancer in men and breast cancer in women. The lifetime risk of developing cancer, which is more related to the individual, is estimated to be higher among men (48.5%) than among women (40.3%). In roughly rounded figures, therefore, about every second person in Germany develops cancer in the course of their lives. One in four men and one in five women die of cancer.
CONCLUSIONS: In recent years, population-based cancer registration in Germany has come significantly closer to the aim of the complete, nationwide coverage of cancer. The continuous improvements in the data situation help describe cancer development in Germany.

Entities:  

Mesh:

Year:  2010        PMID: 20175882      PMCID: PMC2837012          DOI: 10.1186/1471-2407-10-52

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  14 in total

1.  [Cancer incidence estimates for Germany via log-linear models].

Authors:  J Haberland; J Bertz; B Görsch; D Schön
Journal:  Gesundheitswesen       Date:  2001 Aug-Sep

2.  An alternative approach to monitoring cancer patient survival.

Authors:  H Brenner; O Gefeller
Journal:  Cancer       Date:  1996-11-01       Impact factor: 6.860

Review 3.  Interpreting trends in cancer patient survival.

Authors:  P W Dickman; H-O Adami
Journal:  J Intern Med       Date:  2006-08       Impact factor: 8.989

4.  Cancer registry data based estimation of regional cancer incidence: application to breast and colorectal cancer in French administrative regions.

Authors:  M Colonna; P Grosclaude; J Faivre; A Revzani; P Arveux; G Chaplain; B Tretarre; G Launoy; J M Lesec'h; N Raverdy; P Schaffer; A Buémi; F Ménégoz; R J Black
Journal:  J Epidemiol Community Health       Date:  1999-09       Impact factor: 3.710

5.  [Future cancer incidents in Germany].

Authors:  J Haberland; J Bertz; B Görsch; R Dölle; B-M Kurth
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2006-05       Impact factor: 1.513

6.  Estimates of the world-wide prevalence of cancer for 25 sites in the adult population.

Authors:  Paola Pisani; Freddie Bray; D Maxwell Parkin
Journal:  Int J Cancer       Date:  2002-01-01       Impact factor: 7.396

7.  Standard cancer patient population for age standardising survival ratios.

Authors:  Isabella Corazziari; Mike Quinn; Riccardo Capocaccia
Journal:  Eur J Cancer       Date:  2004-10       Impact factor: 9.162

8.  [Federal Cancer Reporting Unit. Surveillance program for cancer registration in Germany].

Authors:  D Schön; J Bertz; B Görsch; J Haberland; B-M Kurth
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2004-05       Impact factor: 1.513

9.  Age-conditional probabilities of developing cancer.

Authors:  Michael P Fay; Ruth Pfeiffer; Kathleen A Cronin; Chenxiong Le; Eric J Feuer
Journal:  Stat Med       Date:  2003-06-15       Impact factor: 2.373

10.  Cancer survival in five continents: a worldwide population-based study (CONCORD).

Authors:  Michel P Coleman; Manuela Quaresma; Franco Berrino; Jean-Michel Lutz; Roberta De Angelis; Riccardo Capocaccia; Paolo Baili; Bernard Rachet; Gemma Gatta; Timo Hakulinen; Andrea Micheli; Milena Sant; Hannah K Weir; J Mark Elwood; Hideaki Tsukuma; Sergio Koifman; Gulnar Azevedo E Silva; Silvia Francisci; Mariano Santaquilani; Arduino Verdecchia; Hans H Storm; John L Young
Journal:  Lancet Oncol       Date:  2008-07-17       Impact factor: 41.316

View more
  19 in total

1.  Inducible expression of tissue factor in small-cell lung cancer: impact on morphology and matrix metalloproteinase secretion.

Authors:  Nicole Hahn; Margarethe Heiden; Rainer Seitz; Ursula Salge-Bartels
Journal:  J Cancer Res Clin Oncol       Date:  2012-01-12       Impact factor: 4.553

2.  Adopting Guidelines into Clinical Practice: Implementation of Trastuzumab in the Adjuvant Treatment of Breast Cancer in Lower Saxony, Germany, in 2007.

Authors:  Clemens Liebrich; Günter Unger; Birgit Dlugosch; Stefan Hofmann; Karl U Petry
Journal:  Breast Care (Basel)       Date:  2011-01-31       Impact factor: 2.860

3.  Comparison between surgical outcomes of colorectal cancer in younger and elderly patients.

Authors:  Longxue Jin; Norio Inoue; Naoki Sato; Susumu Matsumoto; Hitoshi Kanno; Yuko Hashimoto; Kazuhiro Tasaki; Kinya Sato; Shun Sato; Katsutoshi Kaneko
Journal:  World J Gastroenterol       Date:  2011-03-28       Impact factor: 5.742

4.  NDR1 activates CD47 transcription by increasing protein stability and nuclear location of ASCL1 to enhance cancer stem cell properties and evasion of phagocytosis in small cell lung cancer.

Authors:  Ling-Ling Wang; Xiao-Yun Wan; Tao-Li Wang; Chun-Qi Liu; Fei-Meng Zheng
Journal:  Med Oncol       Date:  2022-10-12       Impact factor: 3.738

Review 5.  Cancer stem cells in small cell lung cancer.

Authors:  Jordi Codony-Servat; Alberto Verlicchi; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2016-02

Review 6.  Pancreatic Cancer: Progress in Systemic Therapy.

Authors:  Luka Perkhofer; Thomas J Ettrich; Thoma Seufferlein
Journal:  Gastrointest Tumors       Date:  2015-03-27

7.  Efficacy, compliance and reasons for refusal of postoperative chemotherapy for elderly patients with colorectal cancer: a retrospective chart review and telephone patient questionnaire.

Authors:  Pan Li; Fen Li; Yujing Fang; Desen Wan; Zhizhong Pan; Gong Chen; Gang Ma
Journal:  PLoS One       Date:  2013-02-22       Impact factor: 3.240

8.  (±)Equol inhibits invasion in prostate cancer DU145 cells possibly via down-regulation of matrix metalloproteinase-9, matrix metalloproteinase-2 and urokinase-type plasminogen activator by antioxidant activity.

Authors:  Wei Zheng; Yumei Zhang; Defu Ma; Yuhui Shi; Changqiu Liu; Peiyu Wang
Journal:  J Clin Biochem Nutr       Date:  2012-03-30       Impact factor: 3.114

9.  Life satisfaction and risk of chronic diseases in the European prospective investigation into cancer and nutrition (EPIC)-Germany study.

Authors:  Silke Feller; Birgit Teucher; Rudolf Kaaks; Heiner Boeing; Matthaeus Vigl
Journal:  PLoS One       Date:  2013-08-20       Impact factor: 3.240

10.  High mitochondria content is associated with prostate cancer disease progression.

Authors:  Katharina Grupp; Karolina Jedrzejewska; Maria Christina Tsourlakis; Christina Koop; Waldemar Wilczak; Meike Adam; Alexander Quaas; Guido Sauter; Ronald Simon; Jakob Robert Izbicki; Markus Graefen; Hartwig Huland; Thorsten Schlomm; Sarah Minner; Stefan Steurer
Journal:  Mol Cancer       Date:  2013-11-21       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.